Yes, you should reduce the diltiazem dose immediately due to symptomatic bradycardia
This patient is experiencing symptomatic bradycardia (HR 43 bpm with dizziness) from diltiazem, which is a recognized major side effect of the medication, and dose reduction is clinically indicated. 1, 2
Immediate Management
- Reduce the dose to 180 mg daily (half the current dose) rather than abruptly discontinuing, as this maintains some therapeutic effect while addressing the bradycardia
- Monitor heart rate and symptoms closely over the next 3-5 days, as diltiazem has a half-life of 3.0-4.5 hours and steady-state changes will occur within this timeframe 2
- If symptoms persist or heart rate remains <50 bpm, consider further dose reduction to 120 mg or discontinuation
Evidence Supporting Dose Reduction
The FDA labeling explicitly lists bradycardia (↓HR) and hypotension (↓BP) as major side effects of diltiazem 1, 2. The ACC/AHA/ESC guidelines confirm these as Class I recognized adverse effects 1.
Key pharmacologic considerations:
- Diltiazem decreases sinoatrial and atrioventricular conduction, with dose-dependent effects on heart rate 2
- In patients with sick sinus syndrome, diltiazem can prolong sinus cycle length by up to 50% 2
- The dose-response relationship is non-linear: increasing from 240 mg to 360 mg daily produces a 1.8-fold increase in drug exposure (AUC), meaning the patient is experiencing disproportionately high drug effects 2
Dosing Evidence
Research demonstrates that 180-240 mg daily is effective for most indications:
- Studies show 240-360 mg doses provide adequate blood pressure control with acceptable side effect profiles 3, 4, 5
- The 360 mg dose showed increased bradycardia rates (8.1%) in dose-response trials 3
- Lower doses (180-240 mg) maintain therapeutic plasma levels (>40-50 ng/mL) while reducing adverse effects 4, 5
Critical Pitfalls to Avoid
- Do not continue the current dose hoping the patient will "adjust" - symptomatic bradycardia at HR 43 bpm poses fall risk and potential for syncope
- Do not abruptly discontinue if the patient has underlying atrial fibrillation or coronary disease, as rebound tachycardia or ischemia may occur
- Assess for concomitant medications that may potentiate bradycardia (beta-blockers, digoxin, amiodarone) - these combinations amplify the negative chronotropic effect 1
Monitoring After Dose Reduction
Check heart rate and blood pressure within 3-5 days after dose reduction:
- Target heart rate: 60-100 bpm at rest without symptoms
- If HR normalizes (>55 bpm) and dizziness resolves on 180 mg, this becomes the maintenance dose
- If bradycardia persists, reduce to 120 mg or consider alternative agents
The patient's quality of life is currently impaired by dizziness, and the risk of falls or syncope from a heart rate of 43 bpm outweighs any benefit from the higher dose.